InvestorsHub Logo
Followers 826
Posts 119432
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 4982

Tuesday, 11/01/2022 10:05:27 AM

Tuesday, November 01, 2022 10:05:27 AM

Post# of 6070
PFE reports 3Q22 results—raises 2022 guidance:

https://finance.yahoo.com/news/pfizer-reports-strong-third-quarter-104500928.html

2022 guidance for Comirnaty (COVID vaccine) is now $34B (from prior $32B). 2022 guidance of Paxlovid remains $22B.

2022 non-GAAP EPS guidance is now $6.40-6.50 (from the prior range of $6.30-6.45), despite an increased headwind from currency exchange rates (i.e. the strong US dollar).


CC slides:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q3/Q3-2022-Earnings-Charts-FINAL.pdf

Transcript of CC prepared remarks:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q3/Q3-2022-Earnings-Conference-Call-Prepared-Remarks-FINAL-(1).pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PFE News